by Biocross | Dec 27, 2019 | Press release
El SERGAS ha adjudicado a Biocross S.L. el contrato de compra de innovación tecnológica para el desarrollo de servicios de I+D para el diagnóstico precoz en pacientes con patologías relacionadas con neurología, por un importe de 223.000€ dentro del plan de innovación...
by Biocross | Jul 10, 2017 | Press release
El Alzheimer, enfermedad neurodegenerativa, afecta actualmente a 37 millones de personas en todo el mundo y se espera que la cifra aumente a 131 millones en 2050 El test de riesgo ApoE4 Blood Marker Assay es una prueba en sangre, coste-efectiva y contrastada que...
by Biocross | Dec 15, 2016 | Press release
Biocross was pleased to present at the 9th Clinical trials on Alzheimer’s Disease (CTAD) meeting, to be held in San Diego, the ApoE4 blood marker assay, a new non-genetic method to evaluate Alzheimer’s disease risk. To date only the presence of one or two APOE ε4...
by Biocross | Oct 29, 2016 | Press release
Biocross S.L., a biotechnology company focused on the development of innovative technologies for the diagnosis of Alzheimer’s disease and the identification of at-risk individuals, today announced that their Chief Executive Officer Matt Mittino will present the...
by Biocross | Sep 29, 2016 | Press release
Biocross to participate in the 8th International Meeting on Biotechnology, Biospain 2016, which takes place in Bilbao (Vizcaya), September 28–30, 2016. Biospain has become the main scientific, social, commercial, and industrial meeting point of the biotechnological...
by Biocross | Jul 5, 2016 | Press release
Biocross is pleased to present at the 2016 Alzheimer’s Association International Conference (AAIC) in Toronto its work on the influence of APOE ε4 carrier status on the metabolomic profile of AD patients versus cognitively normal controls. The AAIC is the...
